Perioperative coagulopathy in coronary artery bypass surgery

Slides:



Advertisements
Similar presentations
Hemostasis Shaina Eckhouse 10/12/2010.
Advertisements

Transfusion in Cardiopulmonary Bypass. Blood Use & Cardiac Surgery 1971 – average 8 units RBC per case Late 1980’s – Texas Heart Institute 1.4 units per.
Haemostasis Prof. K. Sivapalan.
Brad Beckham T4. Definitions  Major blood loss Hemoglobin concentration below 6-10 g/dl  Massive transfusion in adults >9 erythrocyte units within 24h.
Coagulation, Fluid, and Blood Management for Cardiac Surgery Maureane Hoffman, MD, PhD Professor of Pathology, Duke University and Director, Transfusion.
Basic Clinician Training Module 5
An Overview of Hemostasis
Haemostasis and NovoSeven®
PLATELETS (PLT) Thrombocytes. PLATELETS (PLT) Thrombocytes.
Coagulation (the basics) and recombinant Factor VIIa Mechanism of Action Jerrold H. Levy, MD Emory University School of Medicine and Emory Healthcare Atlanta,
OUTLINE: I.Historical Perspective. A. Development of Thromboelastography. B. The expansion and transition from Cardiac Surgery to Trauma. II.Traditional.
Basic Principles of Hemostasis
Vascular Pharmacology
T: Dr Lelanie Pretorius MBChB, MMed (Haemat), PG Dip (Transfusion Medicine) Dept of Haematology and Cell Biology.
MTP Octaplex rFVIIa Calgary. Massive Transfusion Protocol.
Normal Hemostasis Galila Zaher Consultant Hematologist KAUH.
Dr MOHAMMED H SAIEMALDAHR FACULTY of Applied Medical Sciences
Blood Course By Dr. Khidir Abdel Galil.
Lecture NO- 12- Dr: Dalia Kamal Eldien.  Coagulation: Is the process by which blood changes from a liquid to a clot. Coagulation begins after an injury.
A bleeding diathesis has been recognized in pt. with CCHD, a variety of coagulation abnormalities has been postulated: 1- Polycythemia 2- Hyper viscosity.
Tabuk University Faculty of Applied Medical Sciences Department Of Medical Lab. Technology 3 rd Year – Level 5 – AY
Hemostasis and Blood Coagulation
Hypercoagulable States Basic Clinician Training Module 4 Introduction Hypercoagulable States Test Your Knowledge.
Implant of a Medical Device and the Wound Healing Process.
Basic Clinician Training Module 3
Basic Clinician Training Module 2
Scheme of Coagulation F XIIF XIIa F XIF XIa F IX F X F IXa F VIIaF VII Extrinsic System Tissue damage Release of tissue thromboplastine (F III) Intrinsic.
Coagulation Concepts A review of hemostasis Answers are in the notes pages.
Haemostasis Presented by Dr Azza Serry. Learning Objectives  Definition.  Clotting mechanism.  What keeps blood in fluid status  Control of blood.
Hemostasis & blood coagulation Dr. Wasif Haq. Hemostasis Hemostasis: prevention of blood loss. Is hemostasis same as homeostasis?
Coagulation Mechanisms
Disseminated Intravascular Coagulation. XIIa Coagulation cascade IIa Intrinsic system (surface contact ) XII XI XIa Tissue factor IX IXa VIIa VII VIIIVIIIa.
Role of Factor Concentrates in Perioperative Coagulopathies Dr Neville Gibbs Department of Anaesthesia Sir Charles Gairdner Hospital.
The Clotting Cascade and DIC Karim Rafaat, MD. Coagulation Coagulation is a host defense system that maintains the integrity of the high pressure closed.
Haemostasis Dr.Salah Elmalik Department of Physiology
Objectives At the end of this lecture student should be able to: 1.Recognize different stages of hemostasis 2.Describe formation and development.
Fibrinolysis and Hyperfibrinolysis TEG Analysis
The Biology of Bleeding and Clotting to Death Jeffrey H. Lawson, MD, PhD Director, Vascular Surgery Research Lab Director of Clinical Trials in Vascular.
PLATELETS (PLTs) or Thrombocytes Dr. Taj Platelets Thrombocytes are Fragments of megakaryocytes in bone marrow.
Anticoagulants, Thrombolytic Agents and Antiplatelet Drugs
Coagulation and fibrinolysis
Intrinsic pathway Extrinsic pathway Common pathway The extrinsic pathway was required the addition of an exogenous trigger (originally provided by tissue.
1. Normal haemostasis Haemostasis is the process whereby haemorrhage following vascular injury is arrested. It depends on closely linked interaction.
Bleeding Tendency Dr. Mervat Khorshied Ass. Prof. of Clinical and Chemical Pathology.
Platelets. Fig Hemostasis the process by which the bleeding is stopped from broken vessels. steps involved: Vascular spasm. Platelets plug formation.
Coagulation ICU – RLH Mike Cunningham 11 th December 2008.
Platelets (Thrombocytes)
Venous Thromboembolism-1
HAEMOSTASIS AND THROMBOSIS Regulation of coagulation
These factors prevent blood clotting - in normal state.
Recent advances- Novoseven
Activation of the Hemostatic System During Cardiopulmonary Bypass
Activation of the Hemostatic System During Cardiopulmonary Bypass
2nd Year Medicine- Blood Module May 2008
General Principles of Hemostasis Kristine Krafts, M.D.
Constituents of the blood: Platelets and plasma
Hemodynamic disorders (1 of 3)
and anti-thrombotic pharmocology Tom Williams
Coagulation and Anti-coagulation
Coagulation Cascade of the Newborn
Steps in clotting mechanism
Implant of a Medical Device and the Wound Healing Process.
Perioperative management of the bleeding patient
George J. Despotis, MD, Michael S. Avidan, MD, Charles W. Hogue, MD 
Intrinsic pathway Formation of prothombin activator is the central event in the clotting pathway For its formation the pathway that is initiated by.
Coagulation Disorders Importance in surgical practice
General Principles of Hemostasis Kristine Krafts, M.D.
Drugs Affecting Blood.
Hemostasis Hemostasis depends on the integrity of Blood vessels
Presentation transcript:

Perioperative coagulopathy in coronary artery bypass surgery Dr Lelanie Pretorius MBChB, Mmed (Hemat), PG Dip (Transfusion Medicine) Dept of Haematology University of the Free State November 9, 2018

content Normal haemostasis Mechanisms of peri-operative coagulopathy Laboratory monitoring Management

The major role players Blood platelets Blood vessel endothelium Blood Coagulation factors Blood platelets Inhibitors of coagulation Fibrinolysis 3

Endothelial function

Classic coagulation cascade

EXSTRINSIC INTRINSIC COMMON PATHWAY and contact XIa XI activation XIIa XII Complement and contact XIa XI activation IX IXa VIII, Pl & Ca++ X TISSUE FACTOR PL VII Ca++ X Xa V, Pl & Ca++ II IIa FIBRINOGEN FIBRIN IIa (Thrombin) COMMON PATHWAY

Cell based model of coagulation

Platelet function

Inhibitors of coagulation

Tissue Factor + factor VIIa Factor IXa Factor Xa (+ factor VIII) TFPI Factor IXa (+ factor VIII) Factor Xa (+ factor Va) Anti- thrombin Factor IIa (thrombin) Factor XIa Protein C system Fibrinogen Fibrin

fibrinolysis

INTRINSIC ACTIVATION EXTRINSIC ACTIVATION Factor XIIa Kallikrein Tissue Plasminogen Activator Urokinase-like Activator Fibrin Fragment X Fragment Y + D Fragment E + D Plasminogen Plasmin Streptokinase

Peri-operative coagulopathy Hyper Hypo Fibrino- lysis Peri-operative coagulopathy Antithrombotic drugs Blood components Antifibrinolytic drugs

Mechanism of coagulopathy in CABG Coagulation activation Systemic heparinazation ↓ Platelet nr & fx Fibrinolysis HIGH INTENSITY PREOPERATIVE ANTITHROMBOTIC THERAPY Haemodilution

Activation of coagulation Activation of extrinsic pathway Extensive contact artificial surfaces Surgical trauma – TF release Retransfusion of pericardial blood Consumptive process: contact activation + TF

Impaired haemostasis Haemodilution Hypothermia Systemic heparin Protamine reversal Non-pulsatile flow Haemodilution Hypothermia

↓ Number Adhesion ↓Function Hypothermia Platelets Activation by foreign surface

INCREASED FIBRINOLYSIS Endothelial activation Increased tPA release Contact activation Increased t-PA = extrinsic activation and contact activation = intrinsic activation

Pump prime Trans-fusion Haemodilution Pump prime with balanced physiologic solutions Transfusion of large amounts of salvaged blood

Identify high risk PATIENT FACTORS PROCEDURE FACTORS Advanced age (>70 yrs) Complex aortic Preoperative anaemia Valve/CABG Females Valve Small body size/body surface area CABG Hereditary coagulopathies/plt defects On-pump > off-pump Acquired coagulopathies/plt defects Bilateral internal mammary > SV grafts Cardiogenic shock Urgent/emergent surgery CHF/poor LV function Non-cardiac comorbidities: Renal insufficiency Type II DM – insulin dependent Peripheral vascular disease Sepsis, liver failure, hypoalbuminaemia

Blood conservation strategies Identify high risk pt Limit antithrombotic thx Antifibrinolytic Rx Off-pump CABG Cell salvage device ANH/preop autologous donation Appropriate transfusion indications Selective off-pumt CABG

POC Lab Laboratory monitoring ACT PFA-100 TEG PT/aPTT/TT Fibrinogen FDPs/D-dimers

POC Prolonged by: Hypothermia Haemodilution Thrombocytopenia ACT PFA-100 Value proven in blood conservation TEG

PFA-100 Rapid detection of platelet dysfunction Uniquely simulates the in vivo function of platelets

PFA 100 Injured Blood Vessel PFA-100 Test Cartridge Flow Agonist Collagen Agonist Flow Platelet Plug The system measures platelet function under high shear conditions similar to the environment of a partially occluded blood vessel

PFA 100 Normal Aspirin-like Effect COL/EPI normal Prolonged COL/ADP

TEG measures Viscoelastic changes that occur during coagulation What does it measure? Viscoelastic changes that occur during coagulation Graphical representation of fibrin polymerization Thus measuring: Rate of fibrin polymerization Overall clot strength Complete evaluation Clot initiation Clot formation and Clot stability 29

TEG Guided transfusion Clinical case 57yo female with Marfan syndrome and history of aneurysm presents now with a second aneurysm. Platelet count is approximately 16K.

Normal tracing Platelet count 16K, MA and CI are low. On pump. Lower MA indicates minimal platelet function; clot is mostly fibrin. CI is very low and R slightly elongated, attributable to low levels of phospholipid surfaces to support the enzymatic reaction. Rewarming. Platelet function is still deteriorating. 12 U platelets given. Post protamine. All parameters are approaching normal. Post-op. After treatment, everything looks normal. The patient's first hour chest tube drainage was less than 100 cc.

Delayed clot formation K R α° MA Heparin Effect Factor deficiency Treatment: Protamine or FFP R K Angle MA 2- 8 min 1- 3 min 55 – 78 deg 53 – 69 mm 13 min 3 min 56 deg 60 mm

Weak clot formation Treatment: FFP, platelets α° MA Treatment: FFP, platelets and possible cryoprecipitate R K Angle MA 2- 8 min 1- 3 min 55 – 78 deg 53 – 69 mm 5 min 6 min 35 deg 42 mm

Minimise blood loss & transfusion Bleeding Surgical Renal failure Sepsis Atrial fibrillation Mortality Non-surgical Minimise blood loss & transfusion

management Blood products Pharmacologic agents

To reduce of peri-operative bleeding and aim at blood conservation Pharmacologic agents To reduce of peri-operative bleeding and aim at blood conservation

Drugs used to reduce blood loss Limit use of high intensity anti-thrombotics Discontinue clopidogrel 5 – 7 days pre-op DDAVP Tranexamic acid rFVIIa (Novo-seven) Aprotonin – Drug removed from market PCC – further investigation needed

Drugs ass with ↑ periop blood loss Dipyrimadole Thienopyridines GP inhibitors LMWH Direct thrombin inhibitors

Blood products RCC Improve oxygen carrying capacity FFP Coagulation factor deficiency Cryoprecipitate Source of fibrinogen Hypofibrinogenaemia/fibrinolysis Platelets: Plt < 50 or abnormal BT/PFA-100/TEG

Replaced by isotonic crystalline/colloid solutions Additional transfusion related methods Pre-op autologous Elective Epo ANH 1 or 2 U blood removed Replaced by isotonic crystalline/colloid solutions

Other strategies used Dose of protamine: 50% of heparin dose Heparin-bonded circuits Low prime volume/retrograde autologous priming Intraoperative use of red blood cell salvage Off-pump CABG

The Society of Thoracic Surgeons Blood Conservation Guideline Task Force, 2007: 83 (5): S27 – S86. Perioperative coagulopathy, bleeding and hemostasis during cardiac surgery. Makar et al. ICU Director,